The study included 5,716 asymptomatic adults with an average age of 69 years (56.7% women) who were examined from 2008 to 2009 as part of the BioImage project, which examined a US population to ...

Atherosclerosis is a systemic disease of the large arteries, and activation of inflammatory pathways is important in its pathogenesis1. Increasing evidence supports the importance of CD40–CD154 ...

Progression of subclinical atherosclerosis predicts all-cause mortality risk A study published in The Journal of the American College of Cardiology (JACC) demonstrates that the burden and ...

The progression of atherosclerosis in people who have no symptoms of it is independently associated with the risk of dying from any cause, according to a new study led by researchers from Mount ...

The Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) study demonstrated that intensive LDL-C lowering has a beneficial impact on plaque progression.

The progression of atherosclerosis, at a cellular level, is reminiscent of the processes involved in tumor growth, new research confirms. Importantly, the idea itself is not new—but until now, the ...

Moreover, progression of carotid atherosclerosis provided further prognostic information and was independently associated with all-cause mortality.

Atherosclerosis progression by different LPL markers. a, Location of markers. Location of polymorphisms in the LPL gene was assembled from Genbank accession nos. G187209, G34390, M76722, and ...

Get Instant Summarized Text (Gist) Variations in mRNA length occur during atherosclerosis progression, with mRNAs showing shorter 5'UTR, 3'UTR, and coding regions.

AUSTIN, Texas -- The diuretic spironolactone stopped the progression of atherosclerosis in people with type 2 diabetes and chronic kidney disease (CKD), according to the MAGMA trial.

Researchers have developed an injectable form of DHA, an omega-3 fatty acid, that is effective in halting the progression of the arterial fatty plaques that can lead to heart attack and stroke.